The story of Viagra offers a intricate case study for investors eyeing pharma. While initial sales were astounding, current patent expiry and the emergence of cheaper versions have considerably affected earnings. In https://keziauyzu811956.blogcudinti.com/41152802/viagra-and-big-pharma-a-risky-bet